Skip to main content
OpenTrials

Clinical trial condition

Orbital Diseases

Explore clinical trials studying Orbital Diseases. Study availability and eligibility vary by location and protocol.

251 public trials 69 recruiting studies
Refine in advanced search Browse all conditions

Orbital Diseases trial results

Completed

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

NCT06384547

Conditions
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine System Diseases, +12 more
Locations
  • United Medical Research Institute Inglewood, California, United States
  • Advancing Research International, LLC Los Angeles, California, United States
  • Stanford Byers Eye Institute Palo Alto, California, United States
  • Cockerham Eye Consultants, PC San Diego, California, United States
View all 50 locations
View Trial Details
Completed

An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)

NCT06179875

Conditions
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine System Diseases, +12 more
Locations
  • Advancing Research International, LLC Los Angeles, California, United States
  • USC Eye Institute Los Angeles, California, United States
  • Advancing Research International, LLC Newport Beach, California, United States
  • Stanford Byers Eye Institute Palo Alto, California, United States
View all 45 locations
View Trial Details
Completed

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

NCT05524571

Conditions
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine System Diseases, +12 more
Locations
  • Site Number -1520 Pasadena, California, United States
  • Site Number -1517 San Francisco, California, United States
  • Site Number -1514 Torrance, California, United States
  • Site Number -1510 Sarasota, Florida, United States
View all 45 locations
View Trial Details
Completed

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

NCT05002998

Conditions
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine System Diseases, +12 more
Locations
  • The Private Practice of Raymond Douglas, MD - Beverly Hills Beverly Hills, California, United States
  • USC Roski Eye Institute - Los Angeles Los Angeles, California, United States
  • Stanford University Palo Alto, California, United States
  • University of Colorado - Eye Center - PPDS Aurora, Colorado, United States
View all 28 locations
View Trial Details

Related conditions